Barely Significant
← all excerpts

Recombinant human nerve growth factor (cenegermin) for moderate-to-severe dry eye: phase II, randomized, vehicle-controlled, dose-ranging trial.

BMC Ophthalmol · 2024 · PMC11253442 · PMID 39020305

Europe PMCDOI
1
hedged sentence
0.0380
closest p · 0.8× alpha
0.0380
boldest claim

The sentences

trending toward significanceP = 0.038actually significant
group significantly improved in patients with Sjögren’s DED (global, P = 0.011; severity, P = 0.002) and improved trending toward significance in patients with non-Sjögren’s DED (global, P = 0.038; severity, P = 0.081).

also in 100 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.